BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 75,631 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 75,631 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $307.79, for a total transaction of $23,278,465.49. Following the sale, the chief executive officer owned 24,369 shares in the company, valued at $7,500,534.51. The trade was a 75.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

John Oyler also recently made the following trade(s):

• On Tuesday, December 16th, John Oyler sold 24,369 shares of BeOne Medicines stock. The stock was sold at an average price of $302.87, for a total transaction of $7,380,639.03.

BeOne Medicines Price Performance

ONC stock traded up $1.74 during trading on Wednesday, reaching $306.05. The company’s stock had a trading volume of 245,211 shares, compared to its average volume of 383,520. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03. The company’s fifty day moving average is $329.62 and its 200-day moving average is $306.92. The company has a market capitalization of $36.28 billion, a P/E ratio of 600.10 and a beta of 0.45. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $170.99 and a 1 year high of $385.22.

Analyst Upgrades and Downgrades

ONC has been the topic of a number of research analyst reports. Citigroup boosted their price target on BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Truist Financial set a $400.00 price objective on shares of BeOne Medicines in a research report on Monday, November 24th. Royal Bank Of Canada restated an “outperform” rating on shares of BeOne Medicines in a research report on Wednesday. Jefferies Financial Group reiterated a “buy” rating and issued a $420.00 price target on shares of BeOne Medicines in a report on Monday, November 17th. Finally, Barclays started coverage on shares of BeOne Medicines in a report on Thursday, September 18th. They set an “overweight” rating and a $385.00 price objective for the company. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, BeOne Medicines has an average rating of “Moderate Buy” and an average target price of $365.79.

Institutional Investors Weigh In On BeOne Medicines

Large investors have recently bought and sold shares of the business. Primecap Management Co. CA bought a new stake in shares of BeOne Medicines during the 2nd quarter worth approximately $1,231,720,000. Capital International Investors increased its stake in BeOne Medicines by 3.3% in the third quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock worth $1,716,883,000 after purchasing an additional 161,052 shares during the period. Temasek Holdings Private Ltd bought a new stake in shares of BeOne Medicines during the second quarter worth $244,603,000. Marshall Wace LLP bought a new stake in shares of BeOne Medicines during the second quarter worth $113,190,000. Finally, Bank of America Corp DE boosted its stake in shares of BeOne Medicines by 23.5% during the third quarter. Bank of America Corp DE now owns 345,256 shares of the company’s stock valued at $117,629,000 after purchasing an additional 65,763 shares during the period. Institutional investors own 48.55% of the company’s stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.